免疫检查点抑制剂相关主动脉炎与大血管炎:FAERS药物警戒分析
基于FAERS 2011Q1至2025Q3数据,回顾性分析免疫检查点抑制剂(ICI)相关主动脉炎和经典大血管炎报告83例,中位年龄68岁,57.8%为男性,住院率34.9%、死亡率2.4%,中位起病时间105.5天。整体呈阳性不成比例报告信号(ROR 4.45;95%CI 3.57-5.55),以抗PD-1药物、纳武利尤单抗、帕博利珠单抗、伊匹木单抗及伊匹木单抗联合纳武利尤单抗最明显。
要点
- ICI相关主动脉炎和大血管炎罕见但可致住院(34.9%)甚至死亡(2.4%)。
- 整体阳性信号ROR 4.45(95%CI 3.57-5.55),抗PD-1药物ROR 4.32(95%CI 3.27-5.71)。
- 主动脉炎与巨细胞动脉炎呈阳性信号,大动脉炎报告极少。
核心结论
- FAERS分析发现ICI相关主动脉炎和经典大血管炎存在不成比例报告信号,属罕见但可能严重的毒性,需警惕但结果仅用于生成假设,不能推断发生率或因果关系。
研究设计与样本
- 回顾性药物警戒分析,数据来自FAERS 2011Q1至2025Q3报告,以MedDRA首选术语「Aortitis」「Giant cell arteritis」「Takayasu's arteritis」识别病例,ICI暴露定义为主要或次要怀疑药物。
主要发现
- 共识别83例ICI相关主动脉炎和经典大血管炎报告,中位年龄68岁,57.8%为男性。
- 住院和死亡分别报告于34.9%和2.4%的病例;有起病数据的报告中位起病时间105.5天。
- 整体呈阳性不成比例信号(ROR 4.45;95%CI 3.57-5.55),抗PD-1药物信号明显(ROR 4.32;95%CI 3.27-5.71),纳武利尤单抗、帕博利珠单抗、伊匹木单抗及伊匹木单抗联合纳武利尤单抗亦见信号。
- 事件亚型层面,主动脉炎和巨细胞动脉炎呈阳性信号,大动脉炎报告罕见。
关键数值与推荐
- 不成比例分析采用报告比值比(ROR)、比例报告比、信息成分和经验贝叶斯几何均值,并按ICI类别、单药、方案及事件亚型进行亚组分析。
临床怎么用
- ICI治疗期间出现不明原因炎症症状或血管影像异常时,临床医生应考虑这一罕见但可能严重的毒性。
局限性
- 结果为假设生成性,需进一步验证,不能用于推断发生率或因果关系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Immune checkpoint inhibitors (ICIs) may induce rare immune-related vascular toxicities, but evidence on ICI-associated aortitis and classical large-vessel vasculitis remains limited. This study characterized clinical features and disproportionality signals using the FDA Adverse Event Reporting System (FAERS). METHODS: FAERS reports from 2011 Q1 to 2025 Q3 were retrospectively analyzed. Cases were identified using the MedDRA Preferred Terms "Aortitis," "Giant cell arteritis," and "Takayasu's arteritis." ICI exposure was defined as an ICI recorded as the primary or secondary suspect drug. Clinical characteristics were summarized descriptively. Disproportionality was assessed using reporting odds ratio (ROR), proportional reporting ratio, information component, and empirical Bayesian geometric mean, with subgroup analyses by ICI class, individual agent, regimen, and event subtype. RESULTS: We identified 83 reports of ICI-associated aortitis and classical large-vessel vasculitis. The median age was 68 years, and 57.8% of patients were male. Hospitalization and death were reported in 34.9% and 2.4% of cases, respectively. Among reports with available onset data, the median time to onset was 105.5 days. ICIs showed a positive disproportionality signal overall (ROR, 4.45; 95% CI, 3.57-5.55). Signals were most evident for anti-PD-1 agents (ROR, 4.32; 95% CI, 3.27-5.71), nivolumab, pembrolizumab, ipilimumab, and ipilimumab plus nivolumab. At the event-subtype level, aortitis and giant cell arteritis showed positive signals, whereas Takayasu's arteritis was rarely reported. CONCLUSION: This FAERS analysis identified disproportionate reporting signals for ICI-associated aortitis and classical large-vessel vasculitis. Clinicians should consider this rare but potentially serious toxicity in patients with unexplained inflammatory symptoms or abnormal vascular imaging during ICI therapy. These findings are hypothesis-generating and require validation, and they cannot be used to infer incidence or causality.
引用
- Guo Q, Guo H. Immune checkpoint inhibitor-associated aortitis and classical large-vessel vasculitis: Clinical characterization and pharmacovigilance analysis using FAERS. Semin Arthritis Rheum. 2026. PMID: 42623759. doi:10.1016/j.semarthrit.2026.153057
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。